OraSure Technologies (NASDAQ:OSUR) announced its quarterly earnings results on Wednesday. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01, Briefing.com reports. The firm had revenue of $52.00 million for the quarter, compared to the consensus estimate of $50.20 million. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. The company’s quarterly revenue was up 46.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.13 earnings per share.
OraSure Technologies (NASDAQ OSUR) traded down $2.08 during mid-day trading on Thursday, reaching $18.25. The company’s stock had a trading volume of 1,030,155 shares, compared to its average volume of 635,055. OraSure Technologies has a 52 week low of $9.92 and a 52 week high of $23.01. The company has a market capitalization of $1,222.67, a P/E ratio of 35.14, a price-to-earnings-growth ratio of 4.48 and a beta of 1.43.
A number of research analysts have recently issued reports on OSUR shares. Canaccord Genuity reaffirmed a “buy” rating and set a $24.00 price target on shares of OraSure Technologies in a report on Friday, February 2nd. BidaskClub raised OraSure Technologies from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. Zacks Investment Research raised OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a report on Wednesday, October 25th. Jefferies Group reaffirmed a “buy” rating and set a $23.00 price target on shares of OraSure Technologies in a report on Friday, October 20th. Finally, ValuEngine downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. OraSure Technologies presently has an average rating of “Buy” and a consensus price target of $20.05.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.